WO2004096265A1 - Nutriment liquide contenant une hormone de croissance humaine et procede de preparation correspondant - Google Patents
Nutriment liquide contenant une hormone de croissance humaine et procede de preparation correspondant Download PDFInfo
- Publication number
- WO2004096265A1 WO2004096265A1 PCT/CN2003/000698 CN0300698W WO2004096265A1 WO 2004096265 A1 WO2004096265 A1 WO 2004096265A1 CN 0300698 W CN0300698 W CN 0300698W WO 2004096265 A1 WO2004096265 A1 WO 2004096265A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino acid
- heme iron
- weishengli
- active peptide
- minutes
- Prior art date
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 18
- 102000002265 Human Growth Hormone Human genes 0.000 title abstract description 4
- 108010000521 Human Growth Hormone Proteins 0.000 title abstract description 4
- 239000000854 Human Growth Hormone Substances 0.000 title abstract description 4
- 235000015097 nutrients Nutrition 0.000 title abstract 3
- 238000002360 preparation method Methods 0.000 title description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 40
- 150000001413 amino acids Chemical class 0.000 claims abstract description 23
- 150000003278 haem Chemical class 0.000 claims abstract description 20
- 229910052742 iron Inorganic materials 0.000 claims abstract description 20
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims abstract description 13
- OVGXLJDWSLQDRT-UHFFFAOYSA-L magnesium lactate Chemical compound [Mg+2].CC(O)C([O-])=O.CC(O)C([O-])=O OVGXLJDWSLQDRT-UHFFFAOYSA-L 0.000 claims abstract description 13
- 229960004658 magnesium lactate Drugs 0.000 claims abstract description 13
- 235000015229 magnesium lactate Nutrition 0.000 claims abstract description 13
- 239000000626 magnesium lactate Substances 0.000 claims abstract description 13
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims abstract description 12
- 229960001471 sodium selenite Drugs 0.000 claims abstract description 12
- 235000015921 sodium selenite Nutrition 0.000 claims abstract description 12
- 239000011781 sodium selenite Substances 0.000 claims abstract description 12
- 235000011478 zinc gluconate Nutrition 0.000 claims abstract description 12
- 239000011670 zinc gluconate Substances 0.000 claims abstract description 12
- 229960000306 zinc gluconate Drugs 0.000 claims abstract description 12
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 claims abstract description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 25
- 239000011858 nanopowder Substances 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 6
- 238000004806 packaging method and process Methods 0.000 claims description 2
- 238000009924 canning Methods 0.000 claims 1
- 230000036039 immunity Effects 0.000 abstract description 2
- 229960003284 iron Drugs 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 13
- 239000003925 fat Substances 0.000 description 8
- 229940100688 oral solution Drugs 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 8
- 230000032683 aging Effects 0.000 description 7
- 210000003205 muscle Anatomy 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 6
- 230000002708 enhancing effect Effects 0.000 description 5
- 230000036737 immune function Effects 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 108010017842 Telomerase Proteins 0.000 description 4
- 108091035539 telomere Proteins 0.000 description 4
- 102000055501 telomere Human genes 0.000 description 4
- 210000003411 telomere Anatomy 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000036299 sexual function Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000016261 weight loss Diseases 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000033830 Hot Flashes Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010050031 Muscle strain Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000037237 body shape Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 230000003803 hair density Effects 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- -1 heme hydrazone Chemical class 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 206010021654 increased appetite Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 230000036562 nail growth Effects 0.000 description 1
- 230000004297 night vision Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 229940041678 oral spray Drugs 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 201000010041 presbyopia Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/315—Zinc compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Definitions
- the invention relates to the field of biotechnology, in particular to an oral solution capable of delaying or even reversing senescence and enhancing immune function, and a preparation method thereof.
- the purpose of the present invention is to overcome the shortcomings of the prior art mentioned above and provide a vitality oral solution capable of delaying aging and enhancing immune function. It mainly solves the problems of large amount of existing products, large side effects, high cost, short storage time of active factors, and low utilization of active ingredients.
- Another object of the present invention is to provide a method for preparing a vitality liquid.
- the present invention is achieved as follows: Weishengli oral liquid, which is composed of the following components by weight parts, active peptides 0. 15-0. 50, amino acids 50- 100, heme iron 20-80 , Sodium selenite 0.30-0. 80, magnesium lactate 0.18-0. 30, zinc gluconate 0.25-0. 50.
- a preferred embodiment of the present invention is that the weight ratio of each component is: active peptide 0.18-0. 40, amino acid 55-80, heme iron 30-60, sodium selenite 0. 35-0. 60, magnesium lactate 0. 19-0. 25, zinc gluconate 0. 28-0. 40.
- a best embodiment of the present invention is that the weight ratio of each component is: active peptide 0.20, amino acid 58, heme iron 35, sodium selenite G. 40, magnesium lactate 0. 20, zinc gluconate 0.30.
- the method for preparing the Weishengli oral liquid according to the present invention comprises the following process steps:
- the first step is ozone treatment. Weigh each component and treat it with ozone;
- the second step is to prepare nano powder. Put amino acid and heme iron into compound high-shear crushing disperser to prepare nano powder;
- the third step is ultrasonic mixing. Transfer the nano-powder into the ultrasonic mixer, add active peptides after 30 minutes, continue mixing for 60 minutes, and freeze to -18 ° C;
- the fourth step is mixing. Blend each component at 2 ° C, mix well;
- the fifth step is packaging. ⁇ Use sterile cans to make finished products.
- the active peptide HGH of the present invention is an abbreviation of Human Growth Hormone, and is also called human growth hormone. It is a physiologically active substance secreted by the endocrine glands. The body's most important hormone (protein peptide), which is composed of 191 amino acid molecules, is the commander of all other hormones.
- the Weishengli oral liquid of the present invention is based on the traditional knowledge of traditional Chinese medicine for thousands of years, combined with the achievements of modern pharmacological research and the latest cutting-edge bioengineering technology.
- Human free radicals have significant functions all the way to thinking and emotion. It can fight diseases, activate the immune system, make people less sick, increase physical strength, Energizing, working long hours without feeling tired. Reveals a person's mental outlook, full of confidence, and high emotions. Revitalizes skin and bones. And it is an effective weight-loss medicine to reshape the body, selectively reduce deep fat in the waist, abdomen and thigh, and increase muscle. Regenerate organs such as liver, lungs, and kidneys, and restore organs and tissues to a younger level.
- telomeres decreases with cell division. At a certain level, "telomeres" disappear, cells stop dividing, and people will age and die.
- telomere is controlled by the “telomerase” in the nucleus. Normally, “telomerase” is in the “off” state, and active peptides (such as HGH, IFG-1) enter the cell through the blood, and it acts on the DNA of "telomerase”, activates telomerase, and makes It is in an “open” state and increases the length of telomeres, thereby delaying aging.
- active peptides such as HGH, IFG-1
- the Weishengli oral liquid of the present invention can promote the increase of immune factors in the human body (including: Cytokines, interleukins 1 and 2, immunoglobulin G, tumor necrosis factor), thereby enhancing the immune function.
- the Weishengli oral liquid provided by the invention provides important active peptides of the human body and promotes the secretion of glands, thereby enabling healthy development of human cells, bones, cartilage, muscles, skin, liver and kidneys, and delaying aging. After inspection, it contains a variety of amino acids and trace elements required by the human body, and various indicators are far higher than the standards of health foods, and the detection indicators of their fungi are far lower than the standards of health foods.
- the Weishengli oral liquid of the present invention has obvious effects after taking it, and the majority of users take deep sleep on the second day after taking it; on the third day, the user's physical strength increases, fatigue is weakened, and his complexion becomes ruddy; one week later, Wet skin, reduced hair loss, increased energy, fast wound healing, reduced local edema, lightened scars, improved vision (presbyopia), reduced fat, increased appetite, improved sexual function, reduced female dryness; after one month, memory significantly increased, Decreased white hair, faded spots, disappeared small facial wrinkles, lightened dark circles, lightened age spots, decreased waist fat, female menopause may resume menstruation, increased immunity, increased endurance, energetic, refractory migraine, high blood pressure The symptoms of vertigo disappeared, and old diseases such as joint pain, rheumatism, and lumbar muscle strain improved significantly; two months, muscle strength increased, fat was further reduced, weight adjustment tended to be normal, fingers, toes Nail growth is improved, sexual function is enhanced, strength is increased, skin is moisturized
- An effect survey conducted in 2001 included 800 people, including entrepreneurs, senior executives, and most doctors, accounting for 20 °. .
- the data of 202 subjects were randomly selected for analysis.
- the 202 people ranged from 36 to 74 years old, and women accounted for 19%.
- the average treatment time of 202 people was 180 days, with a minimum of 1 month and a maximum of 2 years.
- results are as follows: 89% of pathological solutions, 84% of increased cardiac contractility, 85% of reduced cholesterol, 81% of increased muscle, 72% of reduced fat, and 81% of improved endurance, 68% increase in skin thickness, 71% increase in skin elasticity, 61% disappearance of wrinkles, 57% increase in wound healing ability, 58% decrease in hot flashes, and 39% regular menstruation. 78% increase confidence in life, 70% skin thinning and whitening, 89% increase in energy, 73% mood stabilization, 70% resistance to common diseases, 60% increase in memory, old 55% of wounds healed, and 36% were new hair.
- the Weishengli oral liquid according to the present invention has prominent substantive characteristics and significant progress:
- the physiological activity of the active factor can be kept at room temperature for two years;
- the present invention adopts the form of oral spray instead of oral administration, it can be directly absorbed from the oral mucosa under the tongue and enter the blood microcirculation, thereby avoiding the active ingredient being largely decomposed and inactivated in the gastrointestinal tract.
- Example 1 Weigh 0.20g of active peptide, 58g of amino acid, 35g of heme iron, 0.40g of sodium selenite, 0.20g of magnesium lactate, 0.30g of zinc gluconate, and treat with ozone.
- the amino acid and heme iron were put into a compound high-shear crushing and dispersing machine to prepare nano powder. Transfer the nanopowder into the ultrasonic mixer, add the active peptide after 30 minutes and continue mixing for 60 minutes, then freeze to -18 ° C. Formulated at 2 ° C according to the distribution ratio of each group, mixed, and then sterilized canned to prepare the vitality oral solution of the present invention.
- Example 2 Weigh 0.30 g of active peptide, 80 g of amino acid, 40 g of heme iron, 0.46 g of sodium selenite, 0.18 g of magnesium lactate, and 0.35 g of gluconate, respectively, and treat with ozone.
- the amino acid and heme hydrazone were put into a compound high-shear crushing disperser to prepare a nano powder. Transfer the nanopowder into the ultrasonic mixer, add the active peptide after 30 minutes and continue mixing for 60 minutes, then freeze to -18 ° C. Formulated at 2 ° C according to the distribution ratio of each group, mixed, and then sterilized canned to prepare the vitality oral solution of the present invention.
- Example 3 0.18 g of active peptide, 55 g of amino acid, 30 g of heme iron, 0.35 g of sodium selenite, 0.19 g of magnesium lactate, and 0.28 g of zinc gluconate were weighed, respectively, and treated with ozone.
- the amino acid and heme iron are put into a compound high-shear crushing and dispersing machine to prepare a nano powder. Transfer the nanopowder into the ultrasonic mixer, add the active peptide after 30 minutes and continue mixing for 60 minutes, then freeze to -18 ° C. Formulated at 2 ° C according to the distribution ratio of each group, mixed with hooks, and then sterilized canned to prepare the vitality oral solution of the present invention.
- Example 4 Weigh 0.40 g of active peptide, 80 g of amino acid, 60 g of heme iron, 0.60 g of sodium selenite, 0.25 g of magnesium lactate, and 0.40 g of zinc gluconate, respectively, and treat with ozone.
- the amino acid and heme iron are put into a compound high-shear crushing and dispersing machine to prepare a nano powder. Transfer the nano powder to the ultrasonic mixer, add active peptide after 30 minutes and continue mixing for 60 minutes Minutes, then frozen to -18 ° C. Formulated according to the distribution ratio of each group at 2 ° C, mixed, and then aseptically canned to prepare the vitality oral solution of the present invention.
- Example 5 0.15 g of active peptide, 50 g of amino acid, 20 g of heme iron, 0.30 g of sodium selenite, 0.18 g of magnesium lactate, and 0.25 g of zinc gluconate were weighed, respectively, and treated with ozone.
- the amino acid and heme iron are put into a compound high-shear crushing and dispersing machine to prepare a nano powder. Transfer the nanopowder into the ultrasonic mixer, add the active peptide after 30 minutes and continue mixing for 60 minutes, then freeze to -18 ° C. Formulated at 2 ° C according to the distribution ratio of each group, mixed, and then sterilized canned to prepare the vitality oral solution of the present invention.
- Example 6 0.50 g of active peptide, 100 g of amino acid, 80 g of heme iron, 0.80 g of sodium selenite, 0.30 g of magnesium lactate, and 0.50 g of zinc gluconate were weighed and treated with ozone.
- the amino acid and heme iron are put into a compound high-shear crushing and dispersing machine to prepare a nano powder. Transfer the nanopowder into the ultrasonic mixer, add the active peptide after 30 minutes and continue mixing for 60 minutes, then freeze to -18 ° C. Formulated at 2 ° C according to the distribution ratio of each group, mixed, and then sterilized canned to prepare the vitality oral solution of the present invention.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003261569A AU2003261569A1 (en) | 2003-04-30 | 2003-08-20 | Nutrient liquid containing human growth hormone and the preparation method thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN03112375A CN1449819A (zh) | 2003-04-30 | 2003-04-30 | 维生力口服液及其制备方法 |
CN03112375.9 | 2003-04-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004096265A1 true WO2004096265A1 (fr) | 2004-11-11 |
Family
ID=28684011
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2003/000698 WO2004096265A1 (fr) | 2003-04-30 | 2003-08-20 | Nutriment liquide contenant une hormone de croissance humaine et procede de preparation correspondant |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN1449819A (fr) |
AU (1) | AU2003261569A1 (fr) |
WO (1) | WO2004096265A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1932524A1 (fr) * | 2006-12-13 | 2008-06-18 | Ludwig-Maximilians-Universität München | Préparations pharmaceutiques pour le traitement de maladies inflammatoires |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1104434A (zh) * | 1993-11-13 | 1995-07-05 | 西安宝安生物工程有限公司 | 乳酸全营养素及其生产工艺 |
CN1368383A (zh) * | 2001-02-09 | 2002-09-11 | 济南百伦思营养食品有限公司 | 复方激素保健品的配方及其制备方法 |
-
2003
- 2003-04-30 CN CN03112375A patent/CN1449819A/zh active Pending
- 2003-08-20 AU AU2003261569A patent/AU2003261569A1/en not_active Abandoned
- 2003-08-20 WO PCT/CN2003/000698 patent/WO2004096265A1/fr not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1104434A (zh) * | 1993-11-13 | 1995-07-05 | 西安宝安生物工程有限公司 | 乳酸全营养素及其生产工艺 |
CN1368383A (zh) * | 2001-02-09 | 2002-09-11 | 济南百伦思营养食品有限公司 | 复方激素保健品的配方及其制备方法 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1932524A1 (fr) * | 2006-12-13 | 2008-06-18 | Ludwig-Maximilians-Universität München | Préparations pharmaceutiques pour le traitement de maladies inflammatoires |
Also Published As
Publication number | Publication date |
---|---|
AU2003261569A1 (en) | 2004-11-23 |
CN1449819A (zh) | 2003-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2634953C (fr) | Formulations et traitements destines au bien-etre | |
CN109172491A (zh) | 一种具有抗衰老和活血化瘀功能的霜剂及其制备方法 | |
CN111388650A (zh) | 平衡雄性荷尔蒙增强男士魅力的组合物及其制备方法 | |
CN109464348A (zh) | 一种具有美容和改善亚健康症状的霜剂及其制备方法 | |
JPH05505819A (ja) | 尋常性ざ瘡の治療および老化遅延のための組成および方法 | |
Furkatovna | EFFECT OF VITAMIN D DICTION ON BONE MINERAL DENSITY IN MENOPAUSA WOMEN | |
CN101040710A (zh) | 一种内服调节女士内分泌兼外用美容养颜的保健营养冲剂 | |
US20060275505A1 (en) | Method and composition for increasing the alkalinity of the body | |
Furkatovna | Vitamin D Deficiency in Menopausa Women | |
CN112237283A (zh) | 一种阿胶糕及其制造方法 | |
CN104606347A (zh) | 一种治疗肝肾阴虚型绝经后骨质疏松症的中药制剂 | |
CN106937988A (zh) | 一种祛斑调经中药组合物及其制备方法 | |
JPH10120579A (ja) | 津液改善用皮膚外用剤 | |
US7262170B2 (en) | Pharmaceutical composition for reducing vaginal acidity and treatment of vaginitis, and the use thereof | |
WO2004096265A1 (fr) | Nutriment liquide contenant une hormone de croissance humaine et procede de preparation correspondant | |
CN114224963A (zh) | 一种用于增强免疫力缓解体力疲劳的中药制剂及其制备方法 | |
CN106860509A (zh) | 筋骨草胶囊的生产工艺 | |
JPH10114665A (ja) | 津液改善剤及びそれを含有する経口投与用組成物 | |
CN113117028A (zh) | 一种排毒养颜美白的中药组合物及制备方法 | |
JPH10120561A (ja) | 津液改善用皮膚外用剤 | |
RU2222316C2 (ru) | Лечебно-косметическое средство | |
WO2005020746A2 (fr) | Procede d'embellissement | |
Handa | Ayurveda for Health & Beauty | |
WO2005079824A1 (fr) | Boisson ou médicament contenant des extraits de bambou comme ingrédient principal | |
CN113679800A (zh) | 桑叶黄精补肾膏及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |